Form 4: BioAtla Director Mary Ann Gray Granted 23,500 Restricted Stock Units

BioAtla, Inc. Director Mary Ann Gray was granted 23,500 shares of common stock in the form of a time-based restricted stock unit award, vesting in 2026 or at the next annual meeting.

Summary

• Mary Ann Gray, a Director of BioAtla, Inc. (BCAB), was granted 23,500 shares of common stock.
• The shares were granted as a time-based Restricted Stock Unit (RSU) award with a transaction date of June 18, 2025.
• The RSU award vests 100% on the earlier of June 18, 2026, or the next Company annual meeting of stockholders.
• Vesting is contingent upon Ms. Gray's continued service through the vesting date.
• Following this transaction, Mary Ann Gray beneficially owns 77,397 shares of BioAtla Common Stock.

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction (RSU grant) which is a neutral to slightly positive event, indicating ongoing director compensation and alignment with shareholder interests, without revealing significant new financial or operational information.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• This type of equity compensation is a standard practice for retaining and incentivizing experienced board members.

Future Outlook

The RSU award is set to vest on the earlier of June 18, 2026, or the next Company annual meeting of stockholders, subject to the director's continued service.

Industry Context

The granting of Restricted Stock Units (RSUs) to independent directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies generally. It serves as a key component of director compensation, aiming to align the interests of the board with long-term shareholder value creation.

Comparison to Industry Standards

• The RSU grant to Mary Ann Gray is consistent with typical director compensation structures observed in the biotech sector, where equity awards are a significant part of remuneration.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize RSU grants for their non-employee directors, often with similar time-based vesting schedules to promote long-term commitment and performance alignment.

Corporate Governance

Related Party Transactions

• The RSU grant to Mary Ann Gray, a Director of BioAtla, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Vesting of the 23,500 RSU shares on the earlier of June 18, 2026, or the next Company annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

BioAtla, BCAB, SEC Form 4, Restricted Stock Unit, RSU, Director Compensation, Insider Transaction, Equity Grant, Corporate Governance